Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Read more
Projected top 10 orphan drugs worldwide by revenue in 2024 (in billion U.S. dollars)*
Projection of top 10 orphan drugs by global revenue 2024
Published by Matej Mikulic, Jun 6, 2019
This statistic displays a projection of the top 10 global orphan drugs based on revenues in 2024. For that year, it is projected that Roche's and AbbVie's Venclexta will generate some 2.9 billion U.S. dollars in revenue. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Projected top 10 orphan drugs worldwide by revenue in 2024 (in billion U.S. dollars)*
Revenue in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account
only $59 / month *
View for free
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Additional Information

© Statista 2019

Show source

Show detailed source information?
Register for free
Already a member?
Log in
Source

Show sources information
Show publisher information

Release date

April 2019

Region

Worldwide

Survey time period

as of April 2019

Supplementary notes

* Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this statistic. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.

Open this statistic in...
Spanish
Projection of top 10 orphan drugs by global revenue 2024
Published by Matej Mikulic, Jun 6, 2019
This statistic displays a projection of the top 10 global orphan drugs based on revenues in 2024. For that year, it is projected that Roche's and AbbVie's Venclexta will generate some 2.9 billion U.S. dollars in revenue. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Orphan drugs"
  • Market overview
  • Companies
  • Products
The most important statistics
  • Research and development
  • Rare diseases
Further Content: You might find this interesting as well
Statistics
Topics
Orphan drugsGlobal Pharmaceutical IndustryPharmaceutical Industry in the U.S.Diseases
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Menu